Development Pipeline
Tempest is developing a first-in-class oncology pipeline of oral therapeutics with broad potential for patients. The product candidates are designed to treat cancer by direct tumor killing, activating the immune system to kill tumor cells, or a combination of both mechanisms.
“RCC” renal cancer; “HCC” hepatocellular carcinoma; “CCA” cholangiocarcinoma; “FAP” familial adenomatous polyposis; “FPI” First Patient In; “rrMM” relapsed/refractor multiple myeloma, “SLE” lupus